Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: University Hospital Birmingham

Target Recruit Count: 2250

Registration Number: NCT00003893

Locations: 🇬🇧
Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004231

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: University Hospital Birmingham

Target Recruit Count: 2000

Registration Number: NCT00003577

Locations: 🇬🇧
University of Cambridge, Cambridge, England, United Kingdom

Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Children's Hospital Los Angeles

Registration Number: NCT00025324

Locations: 🇺🇸
Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
🇨🇦
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 1 locations

Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Leukemia Research Fund

Registration Number: NCT00004218

Locations: 🇮🇹
Ospedali Riuniti di Bergamo, Bergamo, Italy
🇮🇪
St. James' Hospital, Dublin, Ireland
🇬🇧
North Hampshire Hospital, Basingstoke, England, United Kingdom

and more 82 locations

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: III. Medizinische Klinik Mannheim

Target Recruit Count: 1000

Registration Number: NCT00025402

Locations: 🇩🇪
Tumorzentrum Berlin-Moabit, Berlin, Germany
🇩🇪
Wenckebach - Krankenhaus, Berlin, Germany
🇩🇪
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany

and more 175 locations

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: Genitope Corporation

Registration Number: NCT00017290

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

and more 21 locations

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: CMF regimen
Drug: cyclophosphamide
Drug: fluorouracil
Drug: methotrexate

First Posted Date: 2003-01-27

Last Posted Date: 2024-03-08

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 90

Registration Number: NCT00036868

Locations: 🇷🇸
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
🇫🇷
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇪🇬
National Cancer Institute of Egypt, Cairo, Egypt

and more 10 locations

Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 1800

Registration Number: NCT00003437

Locations: 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-20

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 276

Registration Number: NCT00005603

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy